Showing results (91-100 of 279) with videos related to
Sort By:
Pageof 28
Lung Cancer (Amsterdam, Netherlands)|October 4, 2021
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation studyJeffrey M Clarke, Jyoti D Patel, Francisco Robert, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 22, 2011
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexedD Ross Camidge, Scott A Kono, Xian Lu, et al.Lung Cancer (Amsterdam, Netherlands)|January 27, 2022
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNAThomas E Stinchcombe, Xiaofei Wang, Robert C Doebele, et al.Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung CancerJacob Langston, Tejas Patil, D Ross Camidge, et al.Cancer|December 15, 2018
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancerTerry L Ng, Yiwei Liu, Anastasios Dimou, et al.Molecular Imaging|June 20, 2006
Permeation peptide conjugates for in vivo molecular imaging applicationsKristin E Bullok, Seth T Gammon, Stefania Violini, et al.Future Oncology (London, England)|May 24, 2022
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancerKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancerTyler P Robin, Bernard L Jones, Arya Amini, et al.Clinical Lung Cancer|September 13, 2022
The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX)Tami J Bang, Junxiao Hu, Tejas Patil, et al.Pageof 28